Tous Actualités
Suivre
Abonner Helsinn Healthcare SA

Helsinn Healthcare SA

HELSINN AND CSC announce a license agreement for A ALOXI® in Central and Eeastern Europe

LUGANO, SWITZERLAND, and VIENNA, AUSTRIA (ots)

HELSINN
HEALTHCARE SA, a Swiss pharmaceutical group, and CSC, a
Pharmaceutical company based in AUSTRIA, announce the signing of an
agreement granting CSC the exclusive License and Distribution rights
for ALOXI® (Palonosetron hydrochloride) in Austria and other
countries in Central and Eastern Europe.
ALOXI® is a strong and long acting antiemetic belonging to the
second generation of serotonin (5-HT3) antagonists, the leading class
for the prevention of nausea and vomiting induced by chemotherapy.
Several clinical studies have been conducted on a worldwide basis and
presented in international congresses showed ALOXI® efficacy during
the acute and delayed phase after chemotherapy treatment. The product
is currently commercialized in USA where over a million uses have
been completed successfully.
Last December the CHMP recommended ALOXI® approval in Europe for
the following indications:
  • the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and
  • the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Nausea and Vomiting is still an important medical need for
chemotherapy treated patients. International guidelines are always
updated with novelties to indicate the best treatments available for
the medical community. In 2004 the US National Comprehensive Cancer
Network (NCCN) guidelines indicated ALOXI® as the treatment of choice
for the prevention of acute and delayed nausea and vomiting due to
moderately emetogenic chemotherapies.
"We are delighted to extend our long lasting cooperation with CSC
and enter into this new agreement for ALOXI®", said Dr. Riccardo
Braglia, Managing Director of HELSINN HEALTHCARE SA.  "Many years of
a successful relationship with CSC with our leading NSAID product
AULIN and their great expertise and knowledge about oncology and the
CEE markets have been the driving factors for this agreement. We
believe that CSC will be able to introduce very successfully ALOXI®
to the medical community and to the patients suffering from nausea
and vomiting induced by chemotherapy".
"We are grateful to HELSINN HEALTHCARE SA. that has confirmed its
trust in CSC Pharmaceuticals Group. ALOXI® fits very well with our
onco-biotech line and we are sure that the collaboration between the
two Companies and their outstanding professional performance will
bring this Product in the position of a Market leader in the
therapeutic class of anti emetics", said Dr. Iervant Zarmanian, Chief
Executive Officer of CSC Pharmaceuticals.
About Chemotherapy-Induced Nausea and Vomiting (CINV)
CINV is estimated to affect 85% of cancer patients undergoing
chemotherapy and can result in a delay or discontinuation of
chemotherapy treatments. The supportive care area is becoming of
paramount importance to help patients deal with adverse events of
anticancer therapies. With good supportive care drugs, cancer
patients are able to tolerate the anti-cancer treatment to a greater
extent, improving their chances of completing their treatment course
successfully with a better quality of life.
About ALOXI®
ALOXI® is a selective 5-HT3-receptor antagonist, developed for the
prevention of CINV, with a long half-life of 40 hours and at least 30
times higher receptor binding affinity than currently available
compounds. There have been over 2,800 patients treated during the
phase 3 clinical trials and over 1 million uses after its
commercialization in USA. ALOXI® is effective in preventing both
acute and delayed CINV in patients receiving highly and moderately
emetogenic chemotherapy, the most common chemotherapy regimens used
in the treatment of cancer. For more information about this product
please visit our website: www.palonosetron.net and www.aloxi.com.
About HELSINN HEALTHCARE
HELSINN HEALTHCARE SA is a privately owned pharmaceutical group
with headquarters in Switzerland and is the worldwide licensor of
ALOXI®. HELSINN's core business is the licensing of pharmaceuticals
in niche therapeutic areas. The company's business strategy is to
in-license early-stage new chemical entities and complete their
development from the performance of pre-clinical/clinical studies and
CMC development to the attainment of market approvals in strategic
markets (U.S. and Europe).  HELSINN's products are eventually
out-licensed to its marketing partners for distribution.  The active
pharmaceutical ingredients and the finished dosage forms are
manufactured at HELSINN's cGMP facilities and supplied worldwide to
its customers.  For more information about HELSINN, please visit
www.helsinn.com.
About CSC Pharmaceuticals
CSC Pharmaceuticals is a medium size Pharma Company and a Regional
Player in Central Eastern Europe with a product portfolio ranging
from onco-biotech line to NSAIDs with also a presence in
gynecological and OTC sectors. CSC continued investments in upgrading
 Human Resources gives the company approximately six hundred people
with a level of excellence in Regulatory, Medical and Marketing
activities. For more information about CSC Pharmaceuticals, please
visit www.cscpharma.com.
Contact person HELSINN: 
Rachid BenHamza
Ph.D., Head Business Unit Oncology & Supportive Care.
Tel.    +41/91/985'21'21
E-Mail:  info-hhc@helsinn.com
Contact person CSC Pharmaceuticals:
Dr. Ugo Gennaro
Executive Vice President
Tel.     +43/2262/606'110
E-Mail:   office@csc-Pharma.com

Plus de actualités: Helsinn Healthcare SA
Plus de actualités: Helsinn Healthcare SA
  • 28.02.2005 – 08:00

    Helsinn and Galencia announce a license agreement for Aloxi (Palonosetron) in Greece

    LUGANO, SWITZERLAND, and Athens, GREECE (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and GALENICA, a Pharmaceutical company based in Greece, announce the signing of an agreement granting GALENICA the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in GREECE. ALOXI® is the second generation of serotonine (5-HT3) ...